Molecular Devices has announced that its ClonePix™ 2 System is proven effective for rapidly assessing endogenous G-protein-coupled receptor (GPCR) target protein expression levels in mammalian cell lines and selecting high expressing clones.
Unlike conventional methods and assays that have significant sensitivity and throughput limitations, the ClonePix 2 System provides a unique solution to identify and select a wide range of expression levels of endogenous GPCRs in situ.
The ClonePix 2 System offers the necessary sensitivity to detect endogenous levels of protein limited to cell surface expression by utilizing robust white light and fluorescent imaging, followed by rapid selection of high expressing clones.
This technology platform enables high throughput screening and picking of up to 10,000 mammalian clones in 3 weeks. The ClonePix 2 System thereby maximizes workflow efficiency and increases the probability of finding high quality GPCR expressing cells.
Kevin Chance, President of Molecular Devices, commented: “GPCRs represent the largest and most versatile group of cell surface receptors, and are targets of approximately 50% of pharmaceutical drugs in the marketplace. Selection of high expressing GPCR clones currently poses a major bottleneck in cell-line development. We are pleased to finally offer scientists a highly accurate and efficient, one-step solution to identify and isolate optimal mammalian clones expressing GPCR targets of interest quickly.”
ClonePix Systems for screening and selection of mammalian clones are now used in over 100 laboratories around the world to increase workflow productivity, leaving more time to better characterize target proteins and conduct new projects.
Extending the benefits of the ClonePix 2 System to GPCR target research provides a new method to a rapidly developing sector of the pharmaceutical market.